United States
Hi! I really like writing about biotechnology and clinical trials. I am also really interested in addiction.
From spatial transcriptomics to breakthroughs in patient care.
Emerging technologies bring the fight directly to the cancer cells.
How PROTACs, molecular glues, and macrocycles are reshaping drug discovery in 2026.
2026 Outlook for Graves' Disease, Alloimmune Conditions, and Sjögren's Disease
Applying new tools from cell engineering to compact CRISPR and drug design.
Ongoing efforts to go from "liquid" to "solid" tissues are starting to pay off in multiple diseases.
From spatial transcriptomics to breakthroughs in patient care.
Pioneering drug developers express optimism about AI-based approaches while stressing the importance of wet lab validation and safety assurance.
Representatives from four leading companies highlight emerging basic and clinical research that drives renewed optimism.
To explore the latest breakthroughs in proteomics, GEN spoke with five companies at the forefront of proteomic innovation.
Although artificial intelligence is inevitable, its effective use in clinical trials isn't-not without input from judicious people.
By Tiffany Yesavage, PhD Targeted protein degradation is an emerging technology that has the potential to treat cancer and other diseases in a novel way. Like traditional inhibiting drugs, protein degraders are small molecules. However, they differ from other existing modalities in the way that they harness the cell's natural recycling systems to degrade disease-causing proteins.
Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.
Developers of cancer vaccines take aim at patient-specific tumor mutations, cancer-cell-specific post-translational modifications, and tumor-integrated viral components.
Scientists have progressed from merely provoking an anti-cancer immune response to designing it.
By leveraging AI, drug developers are moving beyond incremental gains in efficiency and engaging previously undruggable targets.
Where cyborgian CAR T cells fall short, naturally occurring immune cells may push through-provided they have been properly recruited and trained.
Emerging biotechs are developing new therapies from rare conditions to coronary artery disease.
Nanopore sequencing offers synthetic biologists unparalleled insights into genetic material, driving innovation despite challenges in read quality and user experience compared to other platforms
The intricate steps in life's molecular choreography can be seen more easily thanks to resonance energy transfer, surface plasmon resonance, and other techniques.
Psoriasis, a chronic inflammatory skin condition, can have a significant impact on patients' quality of life. Adoption of novel and emerging treatments has significantly improved psoriasis care in clinical practice, but challenges remain. The ...
To stem the rising tide of antimicrobial resistance, innovative companies are racing to develop new therapeutics, vaccines, and monitoring tools.
Medical manuscript with authorship credit (2022)
Medical manuscript with authorship credit
A practice CME needs assessment